Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Latest maintenance strategies in multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 25.06.17
Views: 1258

Prof Guillermo Ruiz-Arguelles and Prof McCarthy

Professor McCarthy (Roswell Park Cancer Institute, New York, USA) and Professor Ruiz-Argüelles (Centro de Hematologia y Medicina Interna, Mexico) discuss the latest maintenance strategies in multiple myeloma and how these advances impact the treatment landscape in less developed countries. 

It is noted that the current standard of care in Mexico after initial therapy is mostly thalidomide and dexamethasone (d) until the patient becomes intolerant to thalidomide at which point they switch to lenalidomide (R).

Citing cost as reason for this strategy, Professor Ruiz-Argüelles states how this is an issue for patients in less economically developed countries - amounting to half of the world’s population.

Discussing the latest advances from EHA, conversation moves on to new data presented of ixazomib plus Rd followed by maintenance with single agent ixazomib, as well as current trials involving ixazomib.

Whilst agreeing this would be a ‘better option’ than thalidomide, cost continues to play a role in treatment decisions, with dosing schedules highlighted as a potential solution to this problem.

Clinical trials also represent a route of access to novel treatments, with availability of multinational clinical trials in developing countries being ‘critical’ to increase knowledge in those countries and improve treatment options for patients.

This programme has been supported by an unrestricted educational grant from Takeda.

Related videos

follow us

WIN 2018

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence